Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.
Kanakura, Yuzuru; Ohyashiki, Kazuma; Shichishima, Tsutomu; Okamoto, Shinichiro; Ando, Kiyoshi; Ninomiya, Haruhiko; Kawaguchi, Tatsuya; Nakao, Shinji; Nakakuma, Hideki; Nishimura, Jun-ichi; Kinoshita, Taroh; Bedrosian, Camille L; Ozawa, Keiya; Omine, Mitsuhiro.
Int J Hematol
; 98(4): 406-16, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23934275
Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
Dissecting complement blockade for clinic use.
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
Evolving concepts in the treatment of relapsing multiple sclerosis.
Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
Disease-modifying treatments for multiple sclerosis - a review of approved medications.